Tirzepatide works on two incretin pathways rather than one. Its labeled weight-management indication is for chronic weight management in adults who meet defined criteria, used alongside diet and activity changes, and it also carries an indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
According to its labeling, activating these receptors lowers appetite and calorie intake and delays gastric emptying. The practical effect is reduced appetite and earlier fullness, which supports a reduced-calorie diet rather than replacing it.
The safety profile is comparable in character to other incretin therapies. Gastrointestinal effects are common, and labeling carries a boxed warning regarding thyroid C-cell tumors observed in rodents, with contraindications for personal or family history of medullary thyroid carcinoma or MEN 2.
Risks and limitations
- Common gastrointestinal side effects, particularly during dose escalation.
- Boxed warning regarding thyroid C-cell tumors; specific contraindications apply.
- Serious effects including pancreatitis and gallbladder disease are described in labeling.
- Benefit depends on continued use alongside sustained diet and activity change.
- Supply, cost and coverage can affect whether a plan is realistic for you.